NeuroPace

Update in progress

NPCE (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryMedical Devices

NeuroPace, Inc. is a U.S. medical device company focused on treating drug-resistant focal epilepsy with its RNS System, a brain‑responsive neuromodulation system that delivers real-time treatment at the seizure source. The system includes a neurostimulator, cortical strip and depth leads, a Patient Remote Monitor, and related accessories. It also offers a physician tablet, a secure patient data management system, and the nSight Platform for reports and programming. Headquartered in Mountain View, CA, and founded in 1997, the company sells to hospitals for implantation and replacement procedures.

Company score

Sentiment: 0.18; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.33; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.03; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.14; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive